Article

Wavefront-guided outcomes satisfactory for hyperopia or mixed astigmatism

The U.S. Multicenter Trials of wavefront-guided treatment of hyperopia and mixed astigmatism with the CustomView Ablation System (VISX) indicated that 9 months after treatment both groups had similar good results and patients expressed high levels of satisfaction with the outcomes.

Paris—The U.S. Multicenter Trials of wavefront-guided treatment of hyperopia and mixed astigmatism with the CustomView Ablation System (VISX) indicated that 9 months after treatment both groups had similar good results and patients expressed high levels of satisfaction with the outcomes.

In this study, 112 eyes (56 patients) were treated bilaterally with wavefront-guided LASIK and targeted for emmetropia. The mean patient age was 52 years; the mean sphere was 2 D, the mean cylinder was 0.7 D, and the mean spherical equivalent was 2.4 D, according to Douglas Koch, MD, of Houston, at the annual meeting of the European Society of Cataract and Refractive Surgeons.

"At 6 months postoperatively in the hyperopic group (26 eyes), the mean uncorrected visual acuity (UCVA) levels were 70% with 20/20 or better and 88% 20/25 and at 9 months postoperatively 79% had 20/20 or better and 93% 20/25 or better. At 6 months 95% of eyes were ±1 D of intended correction and 83% were ±0.5 D. Up to 9 months postoperatively, the stability was good," he reported.

One eye lost more than one line of best spectacle-corrected visual acuity (BSCVA) and no eyes lost more than two lines of visual acuity.

"In the mixed astigmatism group (86 eyes), the visual acuity results and the accuracy were comparable to the hyperopic group. The mean sphere decreased from -1.68 to 0.9 D. The cylinder decreased from about 3 D to about 0.5 D. Seventy-seven percent of eyes were within ±0.5 D of the intended sphere, and 56% were within ±0.5 D of the intended cylinder," Dr. Koch reported. In both groups, there was a significant increase in patient satisfaction from preoperatively to postoperatively.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.